Inhibition of the ligands instead of the receptors could be an effective alternative treatment because it was shown that the overexpression of EGFR ligands, for example, TGFA, correlates with poor survival in PDAC [11], colorectal cancer [38], bladder cancer [39] or head and neck cancer [40]. This evidence concerns the gene EGFR and urinary bladder cancer.